Failure to Accurately Disclose Conflicts of Interest in Articles Published in JAMA Oncology

Original Investigation

TILs and Outcomes in HER2 Breast Cancer Treated With Lapatinib and Trastuzumab

Roberto Salgado, MD, PhD; Carsten Denkert, MD, PhD; Christine Campbell, MSc; Peter Savas, MD; Paolo Nuciforo, MD; Claudia Aura, MD; Evandro de Azambuja, MD, PhD; Holger Eidtmann, MD; Catherine E. Ellis, PhD; José Baselga, MD; Martine J. Piccart-Gebhart, MD, PhD; Stefan Michiels, PhD; Ian Bradbury, PhD; Christos Sotiriou, MD, PhD; Sherene Loi, MD, PhD
Original Investigation

ESR1 Mutations in Metastatic Breast Cancer

Sarat Chandarlapaty, MD, PhD; David Chen, PhD; Wei He, PhD; Patricia Sung, PhD; Aliaksandra Samoila, MA; Daoqi You, BS; Trusha Bhatt, MSci; Parul Patel, MS; Maurizio Voi, MD; Michael Gnant, MD; Gabriel Hortobagyi, MD; José Baselga, MD, PhD; Mary Ellen Moynahan, MD
Original Investigation

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy

Debora Fumagalli, MD, PhD; David Venet, PhD; Michail Ignatiadis, MD, PhD; Hatem A. Azim Jr, MD, PhD; Marion Maetens, PhD; Françoise Rothé, PhD; Roberto Salgado, MD, PhD; Ian Bradbury, PhD; Lajos Pusztai, MD, PhD; Nadia Harbeck, MD, PhD; Henry Gomez, MD; Tsai-Wang Chang, MD; Maria Antonia Coccia-Portugal, MD; Serena Di Cosimo, MD; Evandro de Azambuja, MD, PhD; Lorena de la Peña, MD; Paolo Nuciforo, MD; Jan C. Brase, PhD; Jens Huober, MD; José Baselga, MD, PhD; Martine Piccart, MD, PhD; Sherene Loi, MD, PhD; Christos Sotiriou, MD, PhD
Brief Report

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

Eli L. Diamond, MD; Vivek Subbiah, MD; A. Craig Lockhart, MD; Jean-Yves Blay, Prof; Igor Puzanov, MD; Ian Chau, MD; Noopur S. Raje, MD; Jurgen Wolf, Prof Dr; Joseph P. Erinjeri, MD, PhD; Jean Torrisi, MD; Mario Lacouture, MD; Elena Elez, MD; Ferran Martínez-Valle, MD; Benjamin Durham, MD; Maria E. Arcila, MD; Gary Ulaner, MD, PhD; Omar Abdel-Wahab, MD; Bethany Pitcher; Martina Makrutzki, MD; Todd Riehl, PharmD, BCOP; José Baselga, MD, PhD; David M. Hyman, MD
Brief Report

Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors

Ryan N. Ptashkin, MS; Diana L. Mandelker, MD, PhD; Catherine C. Coombs, MD; Kelly Bolton, MD, PhD; Zarina Yelskaya, BS; David M. Hyman, MD; David B. Solit, MD; José Baselga, MD, PhD; Maria E. Arcila, MD; Marc Ladanyi, MD; Liying Zhang, MD, PhD; Ross L. Levine, MD; Michael F. Berger, PhD; Ahmet Zehir, PhD
Viewpoint

Should Failure to Disclose Significant Financial Conflicts of Interest Be Considered Research Misconduct?

Jeffrey R. Botkin, MD, MPH
Comment & Response

Failure to Disclose Conflict of Interest

José Baselga, MD, PhD
Comment & Response

Failure to Accurately Disclose Conflicts of Interest in Article Published in JAMA Otolaryngology–Head & Neck Surgery

José Baselga, MD, PhD

To the Editor I write to take full responsibility for failing to report appropriate conflicts of interest disclosures in articles published in JAMA Oncology and the JAMA Network journals between 2015 and 2018, including 5 articles published in JAMA Oncology.¹^-5 In 3 of these article I had reported receiving personal fees from Roche, and in 2 articles I had reported nothing to disclose. In the interest of full disclosure, I now report the following financial interests and activities that I had been involved from 2013 to the present time, regardless of potential relevance:

“Dr Baselga reports nonfinancial support and reasonable reimbursement for travel from Roche/Genentech; receiving fees from and stock ownership in the following companies: Aura Biosciences (including serving on the board of directors from 2013-2017), Infinity Pharmaceuticals (including serving on the board of directors from 2013-2017), PMV Pharma Biotechnologies (including serving on the scientific advisory board from 2014-present), Juno Therapeutics (acquired by Celgene) (including serving on the scientific advisory board from 2014-2017), Grail (including serving as member or chair of the scientific advisory board from 2016-2018), Varian Medical Systems (including serving on the board of directors from 2017-2018), Bristol-Myers Squibb (including serving on the board of directors from March to September 2018), Seragon (acquired by Roche) (including serving on the scientific advisory board of directors from 2013-2014); stock ownership in ApoGen Biotechnologies (including serving on the scientific advisory board from 2014-present), and Foghorn Therapeutics (including serving on the board from 2017-present); serving as cofounder, receiving fees from, and stock ownership in Tango (formerly Synthetic Lethal) from 2016-present and Northern Biologics (formerly Mosaic Biomedicals) (including serving on the scientific advisory board from 2013-present); receiving consulting and travel fees from Novartis and Eli Lilly; serving as cofounder of Venthera; and serving as investigator on a patent licensed to Memorial Sloan Kettering for use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations and serving as investigator for patents pending assignment to Memorial Sloan Kettering for combination therapy using PDK1 and PI3K inhibitors and inhibition of KMT2D for the treatment of breast cancer.”

I hope that this complete list is helpful to readers and editors as they evaluate the underlying research—of which I remain proud to have been affiliated. I have requested that the articles be corrected online⁶ to provide this complete disclosure and a link to this Letter.

Article Information

Corresponding Author: José Baselga, MD, PhD, Vall d’Hebron Institute of Oncology (VHIO), Cellex Center, C/ Natzaret, 115-117, 08035 Barcelona, Spain (jbaselga@vhio.net).

Published Online: October 26, 2018. doi:10.1001/jamaoncol.2018.5674

Conflict of Interest Disclosure: Dr Baselga reports nonfinancial support and reasonable reimbursement for travel from Roche/Genentech; receiving fees from and stock ownership in the following companies: Aura Biosciences (including serving on the board of directors from 2013-2017), Infinity Pharmaceuticals (including serving on the board of directors from 2013-2017), PMV Pharma Biotechnologies (including serving on the scientific advisory board from 2014-present), Juno Therapeutics (acquired by Celgene) (including serving on the scientific advisory board from 2014-2017), Grail (including serving as member or chair of the scientific advisory board from 2016-2018), Varian Medical Systems (including serving on the board of directors from 2017-2018), Bristol Myers Squibb (including serving on the board of directors from March to September 2018), Seragon (acquired by Roche) (including serving on the scientific advisory board from 2013-2014); stock ownership in ApoGen Biotechnologies (including serving on the scientific advisory board from 2014-present), and Foghorn Therapeutics (including serving on the board from 2017-present); serving as cofounder, receiving fees from, and stock ownership in Tango (formerly Synthetic Lethal) from 2016-present and Northern Biologics (formerly Mosaic Biomedicals) (including serving on the scientific advisory board from 2013-present); receiving consulting and travel fees from Novartis and Eli Lilly; serving as cofounder of Venthera; and serving as investigator on a patent licensed to Memorial Sloan Kettering for use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations and serving as investigator for patents pending assignment to Memorial Sloan Kettering for combination therapy using PDK1 and PI3K inhibitors and inhibition of KMT2D for the treatment of breast cancer.

References

Ptashkin RN, Mandelker DL, Coombs CC, et al. Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors [published online June 5, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.2297 PubMed Google Scholar

Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384-388. doi:10.1001/jamaoncol.2017.5029 PubMed Google Scholar Crossref

Fumagalli D, Venet D, Ignatiadis M, et al. RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial. JAMA Oncol. 2016;3(2):227-234. doi:10.1001/jamaoncol.2016.3824 PubMed Google Scholar Crossref

Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 Clinical Trial. JAMA Oncol. 2016;2(10):1310-1315. doi:10.1001/jamaoncol.2016.1279 PubMed Google Scholar Crossref

Salgado R, Denkert C, Campbell C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1(4):448-454. doi:10.1001/jamaoncol.2015.0830 PubMed Google Scholar Crossref

Missing conflict of interest disclosure [published online October 26, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.5678 Google Scholar

Failure to Accurately Disclose Conflicts of Interest in Articles Published in JAMA Oncology

Others Also Liked

Featured Articles

USPSTF Recommendation Statements

Blogs

Select Your Interests

Failure to Accurately Disclose Conflicts of Interest in Articles Published in JAMA Oncology

See More About

Citation

Download citation file:

Others Also Liked